Immunogenicity of attenuated measles virus engineered to express helicobacter pylori neutrophil-activating protein

Vaccine

Volumn 29, Issue 8, 2011, Pages 1710-1720

  Iankov, Ianko D ^a   Haralambieva, Iana H ^a   Galanis, Evanthia ^a  

^a MAYO CLINIC   (United States)

Author keywords

Attenuated measles virus; Helicobacter pylori; Neutrophil activating protein

Indexed keywords

BACTERIAL PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN LAMBDA CHAIN; INTERLEUKIN 8; MEMBRANE COFACTOR PROTEIN; NEUTRALIZING ANTIBODY; NEUTROPHIL ACTIVATING PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC ENGINEERING; HELICOBACTER PYLORI; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MEASLES VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SINGLE DRUG DOSE; TRANSGENE; TRANSGENIC MOUSE; VIROGENESIS; VIRUS ATTENUATION; VIRUS GENE; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS STRAIN;

EID: 79952705827     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.020     Document Type: Article

References (53)

1. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology 2009;136(6):1863-73.
2. Ferreri AJ, Ernberg I,Copie-Bergman C. Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med 2009;265(4):421-38.
3. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19(3):449-90.
4. FrenckJr RW, Clemens J. Helicobacter in the developing world. Microbes Infect 2003;5(8):705-13.
5. Romano M, Iovene MR, Russo MI, Rocco A, Salerno R, Cozzolino D, et al. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 2008;61(10):1112-5.
6. D'Elios MM, Montecucco C, de Bernard M. Vac A and HP-NAP, Ying and Yang of Helicobacter pylori-associated gastric inflammation. Clin Chim Acta 2007;381(1):32-8.
7. Figueiredo C, Machado JC, Yamaoka Y. Pathogenesis of Helicobacter pylori Infection. Helicobacter 2005;10(Suppl. 1):14-20.
8. Tonello F, Dundon WG, Satin B, Molinari M, Tognon G, Grandi G, et al. The Helicobacter pylori neutrophil-activating proteinisaniron-binding protein with dodecameric structure. Mol Microbiol 1999;34(2):238-46.
9. Zanotti G, Papinutto E, Dundon W, Battistutta R, Seveso M, Giudice G, et al. Structure of the neutrophil-activating protein from Helicobacter pylori. J Mol Biol 2002;323(1):125-30.
10. Brisslert M, Enarsson K, Lundin S, Karlsson A, Kusters JG, Svennerholm AM, et al. Helicobacter pylori induce neutrophil transendothelial migration: role of the bacterial HP-NAP. FEMS Microbiol Lett 2005;249(1):95-103.
11. Polenghi A, Bossi F, Fischetti F, Durigutto P, Cabrelle A, Tamassia N, et al. The neutrophil-activating protein of Helicobacter pylori crosses endothelia to promote neutrophil adhesion in vivo. J Immunol 2007;178(3):1312-20.
12. MontemurroP,Nishioka H,Dundon WG,deBernardM, Del GiudiceG,Rappuoli R, et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a potent stimulant of mast cells. Eur J Immunol 2002;32(3):671-6.
13. Montecucco C, de Bernard M. Molecular and cellular mechanisms of action of the vacuolating cytotoxin (VacA) and neutrophil-activating protein (HP-NAP) virulence factors of Helicobacter pylori. Microbes Infect 2003;5(8):715-21.
14. Nishioka H, Baesso I, Semenzato G, Trentin L, Rappuoli R, Del Giudice G, et al. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) activates the MAPK pathway in human neutrophils. Eur J Immunol 2003;33(4):840-9.
15. Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F, et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000;191(9):1467-76.
16. Wang CA, Liu YC, Du SY, Lin CW, Fu HW. Helicobacter pylori neutrophil-activating protein promotes myeloperoxidase release from human neutrophils. Biochem Biophys Res Commun 2008;377(1):52-6.
17. Amedei A, Cappon A, Codolo G, Cabrelle A, Polenghi A, Benagiano M, et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006;116(4):1092-101.
18. Codolo G, Mazzi P, Amedei A, Del Prete G, Berton G, D'Elios MM, et al. The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cell Microbiol 2008;10(11):2355-63.
19. Del Prete G, Chiumiento L, Amedei A, Piazza M, D'Elios MM, Codolo G, et al. Immunosuppression of TH2 responses in Trichinella spiralis infection by Helicobacter pylori neutrophil-activating protein. J Allergy Clin Immunol 2008;122(5):908-13.
20. D'Elios MM, Amedei A, Cappon A, Del Prete G, de Bernard M. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunol Med Microbiol 2007;50(2):157-64.
21. D'Elios MM, Codolo G, Amedei A, Mazzi P, Berton G, Zanotti G, et al. Heli-cobacter pylori, asthma and allergy. FEMS Immunol Med Microbiol 2009;56(1): 1-8.
22. Kabir S. The current status of Helicobacter pylori vaccines: are view. Helicobacter 2007;12(2):89-102.
23. Del Giudice G, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev Vaccines 2009;8(8):1037-49.
24. Wilson KT, Crabtree JE. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007;133(1):288-308.
25. Rossi G, Ruggiero P, Peppoloni S, Pancotto L, Fortuna D, Lauretti L, et al. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infect Immun 2004;72(6):3252-9.
26. Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, Novicki D, et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008;135(3):787-95.
27. Griffin D. Measles virus. In: Knipe DM, Howley PM, editors. Field's virology. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1401-41.
28. Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, et al. Attenuated measles virus as a vaccine vector. Vaccine 2007;25(16): 2974-83.
29. del Valle JR, Devaux P, Hodge G, Wegner NJ, McChesney MB, Cattaneo R. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 2007;81(19):10597-605.
30. Desprès P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005;191(2):207-14.
31. Guerbois M, Moris A, Combredet C, Najburg V, Ruffié C, Février M, et al. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 2009;388(1):191-203.
32. Liniger M, Zuniga A, Morin TN, Combardiere B, Marty R, Wiegand M, et al. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 2009;27(25-26):3299-305.
33. Iankov ID, Hillestad ML, Dietz AB, Russell SJ, Galanis E. Converting tumor-specific markers into reporters of oncolytic virus infection. Mol Ther 2009;17(8):1395-403.
34. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dötsch C, et al. Rescue of measles viruses from cloned DNA. EMBO J 1995;14(23):5773-84.
35. Duprex WP, McQuaid S, Hangartner L, Billeter MA, Rima BK. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999;73(11):9568-75.
36. Campbell AM. Monoclonal antibody and immunosensor technology. Laboratory techniques in biochemistry and molecular biology, vol. 23. Amsterdam: Elsevier; 1991.
37. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256(5517):495-7.
38. Haralambieva IH, Ovsyannikova IG, Vierkant RA, Poland GA. Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity. Clin Vaccine Immunol 2008;15(7):1054-9.
39. Kolakofsky D, Pelet T, Garcin D, Hausmann S, Curran J, Roux L. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol 1998;72(2):891-9.
40. Mrkic B, Pavlovic J, Rülicke T, Volpe P, Buchholz CJ, Hourcade D, et al. Measles virus spread and pathogenesis in genetically modified mice. J Virol 1998;72(9):7420-7.
41. Iankov ID, Pandey M, Harvey M, Griesmann GE, Federspiel MJ, Russell SJ. Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 2006;80(17):8530-40.
42. Tulchinsky TH, Ginsberg GM, Abed Y, Angeles MT, Akukwe C, Bonn J. Measles control in developing and developed countries: the case for a two-dose policy. Bull World Health Organ 1993;71(1):93-103.
43. Lamb RA, Kolakofsky D. Paramyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Field's virology. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1305-40.
44. Kottakis F, Papadopoulos G, Pappa EV, Cordopatis P, Pentas S, Choli-Papadopoulou T. Helicobacter pylori neutrophil-activating protein activates neutrophilsbyits C-terminal region even withoutdodecamer formation, which is a prerequisite for DNA protection-novel approaches against Helicobacter pylori inflammation. FEBS J 2008;275(2):302-17.
45. von Messling V, Milosevic D, Cattaneo R. Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc Natl Acad Sci U S A 2004;101(39):14216-21.
46. Reyes-Del Valle J, Hodge G, McChesney MB, Cattaneo R. Protective antihepatitis B responses in Rhesus monkeys primed with a vectored measles virus and boosted with a single hepatitis B surface antigen dose. J Virol 2009;83(17):9013-7.
47. Taylor JM, Ziman ME, Canfield DR, Vajdy M, Solnick JV. Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. Microb Pathog 2008;44(1):20-7.
48. Necchi V, Candusso ME, Tava F, Luinetti O, Ventura U, Fiocca R, et al. Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori. Gastroenterology 2007;132(3):1009-23.
49. Rupnow MF,Chang AH, Shachter RD, Owens DK, Parsonnet J. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J Infect Dis 2009;200(8):1311-7.
50. Rupnow MF, Shachter RD, Owens DK, Parsonnet J. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 2001;20(5-6):879-85.
51. Low N, Kraemer S, Schneider M, Restrepo AM. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 2008;26(3):383-98.
52. Taylor JM, Ziman ME, Fong J, Solnick JV, Vajdy M. Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations. Infect Immun 2007;75(7):3462-9.
53. Vajdy M, Singh M, Ugozzoli M, Briones M, Soenawan E, Cuadra L, et al. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 2003;110(1):86-94.